Table 2.

First-line treatment: Kaplan–Meier estimates for mOS

First-line treatment	N	%	mOS	Significance
Number of patients	103	100	Months; 95 % CI	Log rank
CTX backbone
Oxaliplatin	41	40	33.6 (24–46.8)	p = 0.24
Irinotecan	58	56	27.6 (18–39.6)
Fluoropyrimidin mono	4	4	49.2 (34.2–.)
Targeted therapy
Anti-VEGF	37	36	27.6 (18–45.6)	p = 0.79
Anti-EGFR	28	27	42 (20.4–72)
None	38	38	30 (24–44.4)
CTX combinations
Oxaliplatin/anti-EGFR	3	3	42 (–)	p = 0.47
Oxaliplatin/anti-VEGF	18	18	25.2 (16.8–48)
Oxaliplatin/none	20	19	26.4 (12–36)
Irinotecan/anti-EGFR	25	24	46.8 (15.6–72)
Irinotecan/anti-VEGF	19	18	28.8 (15.6–46.8)	p = 0.86
Irinotecan/none	14	14	33.6 (16.8–69.6)